Abstract: The compounds of formula I: wherein R.sup.1 --R.sup.9, R.sup.15, A, X, Y, and Z have the meaning given in the specification are active as protein kinase inhibitors and can be used as medicaments, particularly for the treatment of inflammatory skin disorders and alopecia.

Abstract: A compound of the formula ##STR1## useful for treating vitamin D dependent disorders.

Abstract: The compounds of formula I ##STR1## wherein R.sup.1 -R.sup.9, R.sup.15, A, X, Y, Z and n have the meaning given in the specification are active as protein kinase inhibitors and can be used as medicaments, particularly for the treatment of inflammatory skin disorders and alopecia.

Abstract: The compounds of formula I ##STR1## wherein R.sup.1 -R.sup.9, R.sup.15, A, X, Y, Z and n have the meaning given in the specification are active as protein kinase inhibitors and can be used as medicaments, particularly for the treatment of inflammatory skin disorders and alopecia.

Abstract: The compounds are of the class of bi- and tricyclic pyridone derivatives of the formula ##STR1## wherein various substituents are as described in the specification, useful in the control of prevention of muscle tensions, stress conditions, insomnia, anxiety states and/or convulsions.

Abstract: Racemic compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as described herein, enantiomers and diastereomers thereof, and salts of these esters with weak acids, are described. These compounds inhibit pancreas lipase and are useful agents in the treatment of obesity, hyperlipaemia, atherosclerosis and arteriosclerosis.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 independently C.sub.1-17 -alkyl which is saturated or optionally interrupted by up to 8 double or triple bonds and/or optionally interrupted by an O or S atom, which is present in other than the .alpha.-position to an unsaturated C atom; or phenyl, benzyl or --C.sub.6 H.sub.4 --X--C.sub.6 H.sub.5 ring-substituted by 0 to 3 C.sub.1-6 -alkyl-(O or S).sub.1 or 0 groups, and X is oxygen, sulfur or (CH.sub.2).sub.0-3, with the proviso that when R.sup.1 is n-hexyl and R.sup.2 is undecyl or 2Z,5Z-undecadienyl, at least one of the asymmetric C-atoms present in the oxetanone ring and in the .beta.-position to the latter has the R-configuration, an enantiomer or a diastereomer thereof are described. These compounds inhibit pancreas lipase and are useful agents in the treatment of obesity, hyperlipemia, atherosclerosis and arteriosclerosis.

Abstract: The compounds of the formula ##STR1## wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d are defined in the specification and pharmaceutically acceptable addition salts are disclosed. The compounds of formula I have valuable pharmacological properties and can be used for the control of prevention of illnesses. In particular, they have muscle relaxant, seditive-hypnotic, anxiolytic and/or anticonvulsive activity and can accordingly be used in the control or prevention of muscle tensions, stress conditions, isomnia, anxiety states and/or convulsions.

Abstract: The compounds are of the class of bi- and tricyclic pyridone derivatives of the formula ##STR1## wherein the various substituent are as described in the specification, useful in the control of prevention of muscle tensions stress conditions, insomnia, anxiety states and/or convulsions.

Abstract: The invention is directed to a process for the manufacture of pancreatic lipase-inhibiting oxetanone ethyl esters of the formula ##STR1## wherein X is undecyl or 2Z,5Z-undecadienyl; C.sub.6 is n-hexyl; Y is isobutyl and Z is formyl or Y is carbamoylmethyl and Z is acetyl;which process comprises esterifying the corresponding oxetanone ethanols, or hydrogenating the 3-undecenyl group in corresponding oxetanone ethyl ester starting materials to the undecyl group X, or N-formylating or N-acetylating corresponding primary amines.

Abstract: Racemic compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as described herein, enantiomers and diastereomers thereof, and salts of these esters with weak acids, are described. These compounds inhibit pancreas lipase and are useful agents in the treatment of obesity, hyperlipaemia, atherosclerosis and arteriosclerosis.

Abstract: Compounds of the formula ##STR1## wherein Q.sup.1 and the nitrogen atom taken together are a group of the formula >N--CH.sub.2 CH.sub.2 -- (a), >N--CH.sub.2 CH.sub.2 CH.sub.2 -- (b), >N--CH.dbd.CH-- (c), >N--CH.sub.2 --CH.dbd.CH-- (d), >N--CH.sub.2 --S(O).sub.p -- (e), >N--CH.sub.2 CH.sub.2 --S(O).sub.p -- (f) or >N--CH.dbd.CH--S(O).sub.p -- (g), p is the integer 0, 1 or 2, Ra is a phenyl, pyridyl or thienyl group which is optionally substituted by halogen, trifluoromethyl, nitro, lower alkyl or lower alkoxy, Rb and Rc each, independently, are hydrogen, halogen, trifluoromethyl, lower alkyl, lower alkoxy or nitro and the dotted line signifies an optional bond, or Rb and Rc together with the carbon atom denoted by .alpha. are a group of the formula >C.alpha.--S--CH.dbd.CH-- (h), >C.alpha.--CH.dbd.CH--S-- (i) or >C.alpha.--CH.dbd.CH--CH.dbd.

Abstract: The compounds of the formula ##STR1## wherein Ra,R.sub.b,R.sub.c R.sub.d are defined in the specification and pharmaceutically acceptable addition salts are disclosed.The compounds of formula I have valuable pharmacological properties and can be used for the control or prevention of illnesses. In particular, they have muscle relevant, seditive-hypnotic, anxiolytic and/or anticonvulsive activity and can accordingly be used in the control or prevention of muscle tensions, stress conditions, isomnia, anxiety states and/or convulsions.

Abstract: Compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition salt of a compound of formula I which has one or more basic substituents, are described.The compounds of formula I possess pronounced muscle relaxant, sedative-hypnotic, anticonvulsive and anxiolytic properties and have low toxicity.

Abstract: The invention relates to with novel thiazolidine derivatives of the formula ##STR1## wherein X is methylene, oxygen or sulfur; R.sup.1 is halogen; R.sup.2 is hydrogen, nitro, cyano, OR.sup.3 or NHR.sup.3 ; or R.sup.1 and R.sup.2 both simultaneously are hydrogen or nitro; R.sup.3 is hydrogen, alkyl, acyl, --CO--OR.sup.4 or --CO--NHR.sup.4 ; and R.sup.4 is alkyl, unsubstituted or substituted aryl or aralkyl,and their salts with physiologically compatible cations. The compounds of formula I are useful in the treatment of metabolic disorders.

Abstract: Pyrrolidine derivatives of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as hereinafter described, prepared inter alia from the corresponding pyrrolines, are described. The compounds are useful as analgesic agents.

Abstract: Carbamic acid derivatives, processes for their preparation, as well as pesticidal compositions containing the carbamic acid derivatives, and methods for their use, are disclosed.

Abstract: Compounds represented by the formula ##SPC1##Wherein R.sup.1 is a pyridyl, R.sup.2 is hydrogen or lower alkyl, R.sup.3 is hydrogen, lower alkyl or benzyl and R.sup.4 is phenyl or phenyl substituted at one or more carbon atoms with one or more of halogen, lower alkyl, lower alkoxy, nitro or aminoand pharmaceutically acceptable acid addition salts thereof, having analgesic activity are disclosed.